Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
Byrd, J Brown, J O'Brien, S Barrientos, J Kay, N Reddy, N Coutre, S Tam, C Mulligan, S Jaeger, U
Byrd, J
Brown, J
O'Brien, S
Barrientos, J
Kay, N
Reddy, N
Coutre, S
Tam, C
Mulligan, S
Jaeger, U
Citations
Altmetric:
Abstract
In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.
Authors
Byrd, J
Brown, J
O'Brien, S
Barrientos, J
Kay, N
Reddy, N
Coutre, S
Tam, C
Mulligan, S
Jaeger, U
Devereux, S
Barr, P
Furman, R
Kipps, T
Cymbalista, F
Pocock, C
Thornton, P
Caligaris-Cappio, F
Robak, T
Delgado, J
Schuster, S
Montillo, M
Schuh, A
de Vos, S
Gill, D
Bloor, Adrian
Dearden, C
Moreno, C
Jones, J
Chu, A
Fardis, M
McGreivy, J
Clow, F
James, D
Hillmen, P
Brown, J
O'Brien, S
Barrientos, J
Kay, N
Reddy, N
Coutre, S
Tam, C
Mulligan, S
Jaeger, U
Devereux, S
Barr, P
Furman, R
Kipps, T
Cymbalista, F
Pocock, C
Thornton, P
Caligaris-Cappio, F
Robak, T
Delgado, J
Schuster, S
Montillo, M
Schuh, A
de Vos, S
Gill, D
Bloor, Adrian
Dearden, C
Moreno, C
Jones, J
Chu, A
Fardis, M
McGreivy, J
Clow, F
James, D
Hillmen, P
Description
Date
2014-07-17
Publisher
Collections
Keywords
Type
Article
Citation
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. 2014, 371 (3):213-23 N Engl J Med